Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Intravitreal bevacizumab for consecutive multiple choroidal breast metastatic lesions
  1. Ahmad M Mansour,
  2. Ramzi Alameddine
  1. Ophthalmology Department, American University of Beirut, Beirut, Lebanon
  1. Correspondence to Professor Ahmad M Mansour, ammansourmd{at}gmail.com

Summary

A 49-year-old woman presented with visual loss in the right from optic nerve metastatic disease and asymptomatic choroidal lesion at the inferior arcade. Throughout 22 months of follow-up, she developed a total of five different sequential choroidal metastases to the left eye that were non-responsive to chemotherapy but showed prompt tumour regression by fundus examination and fluorescein angiography within 2 weeks after a single intravitreal bevacizumab. The control of the lesion with a single intravitreal injection of bevacizumab reflects the superior choroidal bioavailability of the drug. The persistence of subretinal fluid at the site of prior metastases may be thought to be one sign of persistence of malignant cells, but in the current case and in the literature, it seems a reflection of a diseased retinal pigment epithelium with probable damage from the tumour invasion.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.